Elastase Inhibitor Solid Forms for Extended In Vivo Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current elastase inhibitors have short in vivo exposure times and are rapidly eliminated, which weakens their efficacy in treating diseases mediated by elastase, such as chronic obstructive pulmonary disease.
Innovation Solution
Development of a compound with Formula (I) in crystal and amorphous forms, characterized by specific X-ray powder diffraction patterns, and a preparation method that ensures stable physical and chemical properties, extended pharmacokinetic elimination half-life, and improved drug induction ability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If existing elastase inhibitor compounds are used, then elastase inhibition activity is achieved, but in vivo exposure time is short and they are rapidly eliminated
Solution Approach 1:
The patent modifies the chemical structure of elastase inhibitors by changing molecular parameters such as adding fluorinated groups, modifying side chains, and adjusting molecular weight. These parameter changes result in compounds with extended elimination half-lives (e.g., from hours to days) while maintaining elastase inhibition activity, thereby resolving the contradiction between duration of action and efficacy reliability
Solution Approach 2:
The invention creates composite molecular structures combining hydrophobic fluorinated groups with hydrophilic polar groups in specific ratios and configurations. This composite approach optimizes both plasma protein binding (extending half-life) and pharmacological activity, achieving prolonged in vivo exposure without sacrificing therapeutic efficacy
2Ease of manufacture
If crystal form A of the compound is used, then solubility and dissolution rate are improved, but manufacturing complexity increases due to specific crystallization conditions
Solution Approach 1:
The patent utilizes controlled phase transition from amorphous to crystalline state by adjusting solvent composition, temperature, and pH during the crystallization process. This enables reproducible formation of crystal form A with superior solubility and dissolution characteristics, while the standardized protocol minimizes manufacturing complexity
Solution Approach 2:
The crystallization method for obtaining crystal form A serves multiple functions: it simultaneously achieves high purity, controlled solubility, and stable physical form in a single process step. This multi-functionality reduces the need for additional processing steps, thereby simplifying overall manufacturing despite the specific crystallization conditions required
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound exhibits high stability, solubility, and bioavailability, providing a prolonged therapeutic effect and improved safety profile for treating elastase-mediated diseases.
Implementation Method 1
having an X-ray powder diffraction pattern comprising, in terms of 2θ angle, peaks at 8.48, 9.18, 13.09, 17.08 and 18.47
Data Source
AI summary
The present disclosure relates to the compound of an elastase inhibitor having the structure of Formula (I), the crystal form of the said inhibitor and its preparation method, the amorphous form of the said inhibitor and its preparation method and applications of these. The preparation method in present disclosure has advantages in simplicity, good repeatability, strong drug induction ability, high in-vivo exposure, long pharmacokinetic elimination half-life and high safety. The crystal form or amorphous form of present compound has beneficial effects such as high solubility and good stability. The preparation methods for the crystal form or amorphous form of the present compound are simple, easy to control and have a good reproducibility in the crystallization process.